Radiochemotherapy With Cisplatin and 5-Fluorouracil After Transurethral Surgery in Patients With Bladder Cancer
Journal Article
·
· International Journal of Radiation Oncology, Biology and Physics
- Department of Radiation Therapy, University of Erlangen, Erlangen (Germany)
- Department of Urology, University of Erlangen, Erlangen (Germany)
- Institute of Pathology, University of Erlangen, Erlangen (Germany)
- Department of Radiation Therapy, University of Luebeck, Luebeck (Germany)
- Department of Radiation Therapy, University of Frankfurt, Frankfurt (Germany)
Purpose: To give an update on the long-term outcome of an intensified protocol of combined radiochemotherapy (RCT) with 5-fluorouracil (5-FU) and cisplatin after initial transurethral resection of bladder tumor (TURBT) with selective organ preservation in bladder cancer. Methods and Materials: One hundred twelve patients with muscle-invading or high-risk T1 (G3, associated Tis, multifocality, diameter >5 cm) bladder cancer were enrolled in a protocol of TURBT followed by concurrent cisplatin (20 mg/m{sup 2}/day as 30-min infusion) and 5-FU (600 mg/m{sup 2}/day as 120-h continuous infusion), administered on Days 1-5 and 29-33 of radiotherapy. Response to treatment was evaluated by restaging TURBT 4-6 weeks after RCT. In case of invasive residual tumor or recurrence, salvage cystectomy was recommended. Results: Ninety-nine patients (88.4%) had no detectable tumor at restaging TURBT; 71 patients (72%) have been continuously free from local recurrence or distant metastasis. Superficial relapse occurred in 13 patients and muscle-invasive recurrence in 11 patients. Overall and cause-specific survival rates for all patients were 74% and 82% at 5 years, respectively. Of all surviving patients, 82% maintained their own bladder, 79% of whom were delighted or pleased with their urinary condition. Hematologic Grade 3/4 toxicity occurred in 23%/6% and Grade 3 diarrhea in 21% of patients. One patient required salvage cystectomy due to a shrinking bladder. Conclusion: Concurrent RCT with 5-FU/cisplatin has been associated with acceptable acute and long-term toxicity. Overall and cause-specific survival rates are encouraging. More than 80% of patients preserved their well-functioning bladder.
- OSTI ID:
- 20953558
- Journal Information:
- International Journal of Radiation Oncology, Biology and Physics, Journal Name: International Journal of Radiation Oncology, Biology and Physics Journal Issue: 4 Vol. 68; ISSN IOBPD3; ISSN 0360-3016
- Country of Publication:
- United States
- Language:
- English
Similar Records
Survivin Expression as a Predictive Marker for Local Control in Patients With High-Risk T1 Bladder Cancer Treated With Transurethral Resection and Radiochemotherapy
Management of Superficial Recurrences in an Irradiated Bladder After Combined-Modality Organ-Preserving Therapy
Combined-Modality Therapy With Gemcitabine and Radiation Therapy as a Bladder Preservation Strategy: Long-Term Results of a Phase I Trial
Journal Article
·
Sat Aug 01 00:00:00 EDT 2009
· International Journal of Radiation Oncology, Biology and Physics
·
OSTI ID:21276943
Management of Superficial Recurrences in an Irradiated Bladder After Combined-Modality Organ-Preserving Therapy
Journal Article
·
Tue Apr 01 00:00:00 EDT 2008
· International Journal of Radiation Oncology, Biology and Physics
·
OSTI ID:21124159
Combined-Modality Therapy With Gemcitabine and Radiation Therapy as a Bladder Preservation Strategy: Long-Term Results of a Phase I Trial
Journal Article
·
Mon Jun 01 00:00:00 EDT 2009
· International Journal of Radiation Oncology, Biology and Physics
·
OSTI ID:21276831